October 2019 - Novocure

We have revised our Privacy Policy that is in effect as of May 25, 2018. Please click here to access it.

about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.

ESG report Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
our therapy
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media

press releases

press kits

media gallery

featured stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

179.27

6.23

last update 5/14/2021 16:00pm
careers

our locations

current job listings

Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

October 31, 2019

Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next five years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) …

Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

October 16, 2019

STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial …

Novocure to Report Third Quarter 2019 Financial Results

October 01, 2019

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2019, at …

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
- ESG report Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
our therapy
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media
investor relations
careers
- our locations
- current job listings